Stephen R Lane

Title: The Innovative Contributions of Stephen R. Lane

Introduction

Stephen R. Lane is a notable inventor based in Doylestown, PA (US). He has made significant contributions to the field of oncology, particularly in the treatment of non-small cell lung cancer (NSCLC). His innovative approach combines chemotherapy with targeted immunotherapy, showcasing his commitment to advancing cancer treatment.

Latest Patents

Stephen R. Lane holds a patent for "Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody." This patent outlines a method for treating subjects afflicted with tumors derived from NSCLC. The method involves administering a combination of chemotherapy, an anti-PD-1 antibody or an anti-PD-L1 antibody, and an anti-CTLA-4 antibody. Notably, the chemotherapy is administered for a period shorter than the standard treatment duration, which may enhance patient outcomes.

Career Highlights

Stephen R. Lane is associated with Bristol-Myers Squibb Company, a leading biopharmaceutical company known for its innovative therapies. His work at the company has been instrumental in developing new treatment protocols that aim to improve the lives of cancer patients. His dedication to research and development has positioned him as a key figure in the field of cancer therapeutics.

Collaborations

Throughout his career, Stephen has collaborated with esteemed colleagues, including Sabine Maier and Abderrahim Oukessou. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in cancer treatment methodologies.

Conclusion

Stephen R. Lane's contributions to the field of oncology through his innovative patent and work at Bristol-Myers Squibb Company highlight his dedication to improving cancer treatment. His efforts continue to inspire advancements in medical research and patient care.